Covectra develops new security label for pharmaceutical industry

21 March 2017 (Last Updated March 21st, 2017 18:30)

US-based Covectra has developed a new security label, StellaGUARD, for use in the over-the-counter (OTC) and pharmaceutical sectors.

US-based Covectra has developed a new security label, StellaGUARD, for use in the over-the-counter (OTC) and pharmaceutical sectors.

The patented label is embedded with stars, which are arranged in unique and random patterns and contain a serialised GS1 2D barcode to provide real-time authentication and serialised pedigree tracking.

Covectra has also developed a mobile app, which is linked to the barcode.

Using a smartphone, a user can scan the 2D barcode with a mobile device and take a photographic image, allowing the app’s software to identify and validate the barcode.

"Our new, patented StellaGUARD solution offers two layers of protection, leveraging the benefits of a barcode and connecting it with an image of a random pattern of 'stars' embedded in a label."

Once authenticated, the brand owner can display their product information and customised marketing messages.

Covectra president Steve Wood said: “Our new, patented StellaGUARD solution offers two layers of protection, leveraging the benefits of a barcode and connecting it with an image of a random pattern of 'stars' embedded in a label, providing instantaneous authentication and copy-detect protection.

“Since barcodes can be easily copied, this new solution makes counterfeiting virtually impossible – which is especially critical when it comes to the pharmaceutical industry when counterfeit goods can be life threatening.”

Furthermore, the StellaGUARD label is integrated with Covectra’s Electronic Product Code Information Services (EPCIS) certified AuthentiTrack database, which currently manages over two billion serial numbers and enables the label to be used not just for rapid authentication, but also for diversion detection and isolation.

The label is also made in compliance with the European Union’s (EU) 2019 falsified medicines directive.